{"url_path":"/sec/tbph/8-k/2026-06-29/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1583107/0001104659-26-078453-index.html","accession_number":"0001104659-26-078453","cik":"0001583107","ticker":"TBPH","issuer_name":"Theravance Biopharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1583107/0001104659-26-078453-index.html","primary_entity_key":"0001583107","primary_entity_name":"Theravance Biopharma, Inc."},"word_count":310,"has_tables":true,"body_markdown":"false\n0001583107\n\n0001583107\n\n2026-06-28\n2026-06-28\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, DC  20549**\n\n \n\n \n\n**FORM 8-K**\n\n \n\n \n\n**Current Report Pursuant**\n\n**to Section 13 or 15(d) of the**\n\n**Securities Exchange Act of 1934**\n\n \n\nDate of Report (Date of earliest event reported):\n**June 28, 2026**\n\n \n\n \n\n**THERAVANCE\nBIOPHARMA, INC.**\n\n(Exact Name of Registrant as Specified in its\nCharter)\n\n \n\n \n\n**Cayman Islands**\n \n**001-36033**\n \n**98-1226628**\n\n(State\nor Other Jurisdiction of\n \n(Commission\nFile Number)\n \n(I.R.S.\nEmployer Identification\n\nIncorporation)\n \n \n \nNumber)\n\n \n\n**c/o Theravance Biopharma US, LLC**\n\n**901\nGateway Boulevard**\n\n**South\nSan Francisco****, CA****94080**\n\n**(650****)\n808-6000**\n\n \n\n(Addresses, including zip code, and telephone\nnumbers, including area code, of principal executive offices)\n\n \n\n \n\nCheck the appropriate box below if the Form 8-K\nfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General\nInstruction A.2. below):\n\n \n\n¨\n Written communications pursuant\nto Rule 425 under the Securities Act (17 CFR 230.425)\n\nx\n Soliciting material pursuant to\nRule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n¨\n Pre-commencement communications\npursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n¨\n Pre-commencement communications\npursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\nTitle of each class\n \nTrading\n\nSymbol(s)\n \nName of each exchange\n\non which registered\n\nOrdinary\nShare $0.00001 Par Value\n \nTBPH\n \nNasdaq\nGlobal Market\n\n \n\nIndicate by check mark whether the registrant\nis an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2\nof the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).\n\n \n\nEmerging\ngrowth company    ¨\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨"}